What Is Meningococcal Disease?
A life-threatening bacterial infection causing meningitis and septicaemia, with rapid progression and high fatality if untreated.
Pathogen: Neisseria meningitidis (meningococcus) — serogroups A, B, C, W, X, and Y are the most significant
Type: Bacterium
Transmission
Respiratory droplets and direct contact with nasopharyngeal secretions from carriers or infected individuals (kissing, coughing, sharing drinks, living in close quarters). About 10% of the population are asymptomatic carriers.
Vector: No arthropod vector. Person-to-person via respiratory droplets and direct secretion contact.
Symptoms
Two main presentations. Meningitis: severe headache, neck stiffness, photophobia (light sensitivity), fever, nausea, vomiting, altered consciousness. Septicaemia (meningococcaemia): high fever, a rapidly spreading petechial or purpuric rash (non-blanching), limb pain, cold hands and feet, rapid deterioration, circulatory collapse.
Incubation period: 2 – 10 days
Usually 3-4 days. Can be as short as 2 days. Onset can be explosive, with patients deteriorating within hours of first symptoms.
Timeline: Initial symptoms can mimic a viral illness (fever, irritability, headache). Rapid deterioration over hours. The characteristic non-blanching rash (tumbler test) may appear 12-24 hours after symptom onset. Death can occur within 24 hours of first symptoms.
Case fatality rate: 10-15% even with treatment. Higher for meningococcal septicaemia (up to 40% without treatment). Up to 20% of survivors have long-term sequelae.
Diagnosis & Treatment
Diagnosis: Blood cultures, CSF analysis (lumbar puncture — elevated WBC, low glucose, high protein, Gram-negative diplococci on microscopy). PCR on blood or CSF (most sensitive). Latex agglutination. Do not delay antibiotics waiting for lumbar puncture.
Treatment: Emergency IV antibiotics (ceftriaxone or benzylpenicillin) — must be started immediately on clinical suspicion, before waiting for lab confirmation. Intensive care with fluid resuscitation, vasopressors, and organ support. Dexamethasone may reduce neurological sequelae in bacterial meningitis.
Prevention
- Meningococcal vaccination: ACWY vaccine (Nimenrix or Menveo) and/or MenB vaccine (Bexsero or Trumenba)
- MenACWY is funded on the NIP for adolescents aged 14-16 and recommended for travellers
- MenB is funded on the NIP for Aboriginal and Torres Strait Islander infants and those with specific risk factors
- Avoid sharing drinks, utensils, and cigarettes
- Practice respiratory hygiene (cover coughs and sneezes)
💉 Vaccine Available
A vaccine is available for Meningococcal Disease. View the Meningococcal vaccine guide for details on schedule, cost, and availability in Australia.
Post-Exposure
Close contacts of a confirmed case require antibiotic prophylaxis (ciprofloxacin single dose, or rifampicin, or ceftriaxone) as soon as possible. Vaccination of contacts may also be recommended. Public health authorities manage contact tracing.
Long-Term Effects
Up to 20% of survivors have permanent sequelae: hearing loss, brain damage, seizures, limb amputation (from peripheral gangrene), kidney damage, and chronic pain. Psychological impacts are also significant.
📋 Invasive meningococcal disease is a nationally notifiable disease in Australia. Approximately 200-400 cases are notified annually. Serogroups B and W are currently most common in Australia. The MenACWY vaccine is on the NIP for adolescents.
Frequently Asked Questions
Do I need a meningococcal vaccine for travel?
MenACWY vaccination is recommended for travellers to the African 'meningitis belt' (sub-Saharan Africa from Senegal to Ethiopia), for Hajj/Umrah pilgrims to Saudi Arabia (mandatory), and for travel to countries with current outbreaks. It is also recommended for anyone spending extended time in close-living situations (dormitories, hostels). Discuss your itinerary with a travel doctor.
What is the African meningitis belt?
The meningitis belt stretches across sub-Saharan Africa from Senegal and Guinea in the west to Ethiopia in the east. It includes 26 countries where epidemic meningococcal meningitis occurs regularly, particularly during the dry season (December to June). Serogroup A was historically dominant, but ACWY serogroups now circulate. MenACWY vaccination is strongly recommended for travellers to this region.
Is meningococcal vaccine required for Hajj?
Yes. Saudi Arabia requires proof of meningococcal ACWY vaccination (given within the previous 5 years and at least 10 days before arrival) for all Hajj and Umrah pilgrims. This is a mandatory entry requirement. The vaccine must be documented on the International Certificate of Vaccination (yellow card).
What is the tumbler test for meningococcal disease?
The tumbler test (glass test) involves pressing a clear glass firmly against a rash. If the rash does not fade (non-blanching) when pressed, it may indicate meningococcal septicaemia — a medical emergency. This rash is caused by bleeding under the skin. However, the rash is a late sign — do not wait for it to appear before seeking help if meningococcal disease is suspected.
How quickly does meningococcal disease progress?
Meningococcal disease can progress from initial mild symptoms (fever, irritability) to life-threatening septicaemia or meningitis within hours. A person can appear relatively well in the morning and be critically ill by the afternoon. This is why it is treated as a medical emergency. If meningococcal disease is suspected, go to the emergency department immediately — do not wait for a GP appointment.
What is the difference between meningococcal ACWY and meningococcal B vaccines?
MenACWY vaccine (Nimenrix or Menveo) protects against serogroups A, C, W, and Y. It is the standard travel vaccine and is on the NIP for Australian adolescents. MenB vaccine (Bexsero or Trumenba) protects specifically against serogroup B, which is the most common serogroup causing disease in Australian children and young adults. Both vaccines may be recommended depending on your age, risk factors, and destination.
Can you get meningococcal disease from sharing drinks?
Yes, though casual contact is generally not sufficient. Meningococcal bacteria are transmitted through respiratory secretions, so activities that involve direct exchange of saliva — kissing, sharing drinks, sharing cigarettes — increase transmission risk. Living in close quarters (dormitories, military barracks, backpacker hostels) also increases risk. About 10% of the population carries the bacteria harmlessly in their throat.
Are backpackers at higher risk of meningococcal disease?
Young adults (15-24) are at higher risk generally, and backpackers face additional risk factors: living in close quarters in dormitories and hostels, socialising in crowded environments, fatigue, and potential exposure to carriers from regions with different serogroup prevalence. MenACWY vaccination is recommended for young Australian travellers, particularly those staying in shared accommodation.
Sources & References
Last updated: April 2026